Novartis expands cancer immunotherapy research program with acquisition of CoStim

Main switchboard - Switzerland +41 61 324 11 11 - +41 61 324 80 01 - Monday - Friday, - 8:30 a.m. 5:00 p.m. GMT+1 US switchboard +1 862 778 21 00 - Monday - Friday, - 8:30 a.m. 5:00 p.m. EST More information Global Media Relations - Eric Althoff - Basel, Switzerland +41 61 324 7999 - eric.althoff [a] novartis (p) com More information Investor Relations - Switzerland investor.relations [a] novartis (p) com Monday - Friday, - 8:30 a.m. 5:30 p.m. GMT+1 - (Central European Time) Institutional investors Private investors Report a suspected side effect (also known as an adverse event) related to a Novartis Pharmaceutical drug or a Novartis Vaccine. Reporting side effects Acquisition adds novel immune modulating targets and technology to accelerate Novartis cancer immunotherapy program - Novartis and University of Pennsylvania CAR immunotherapy research combined with CoStim targets and technology strengthens Novartis' position in cancer immunotherapy discovery Basel, February 17, 2014 - Novartis announced today that it is broadening its cancer immunotherapy research program with the acquisition of CoStim Pharmaceuticals Inc., a Cambridge, MA-based, privately held biotechnology company focused on harnessing the immune system to eliminate immune-blocking signals from cancer. Increasing evidence points to the role of the immune system in controlling cancer and to opportunities for creating effective oncology therapies for cancer patients by stimulating a targeted immune response.